- Sales team grows to 65, bringing total number of employees to 95
- The national sales structure is now actively deployed in support of Enerzair® Breezhaler® and Atectura® Breezhaler®
- Expansion of head office and warehouse to support sales growth
MONTREAL, August 16, 2021 /CNW Telbec/ – Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (“Valeo“or the”Society“), a Canadian pharmaceutical company, announced today that it has completed the implementation of its new corporate structure and launched full commercial operations in support of Enerzair Breezhaler triple therapy and Atectura Breezhaler dual therapy , two new asthma drugs.
The company is now structured into 2 business units, Respiratory and Specialty Products, led by industry veterans Howard Wiseman and Jean-Charles Leathead respectively. With the implementation of a complete national sales structure for each business unit, Valeo’s sales team has grown to 65 professionals out of a total of 95 full-time employees. The Company has also recently expanded its head office and warehouse capacity to support its recent product launches.
“Our Respiratory business unit has deployed full commercial coverage across Canada and we are actively collaborating with healthcare professionals to support Enerzair and Atectura,” said Steve Saviuk, CEO. “Our recently completed medical team, led by Nelly Komari, provides us with strong capabilities for our expanding portfolio of innovative medicines. redesca®, Enerzair and Atectura are important launches for us and we expect these three products to drive our sales growth. Launched in April, Redesca has quickly become our fastest growing product line and we continue to believe it will achieve peak sales of $30 million annually”.
Commenting on the completion of the implementation of the new corporate structure, Frederic Fasano, Chairman and Chief Executive Officer of Valeo said: “We are very pleased to have been able to complete the implementation of our new corporate structure and commercially launch three transformative products in such a short time. This is a testament to the quality of our teams in The successful integration of our dedicated sales teams with related head office support functions will create significant operating leverage over the coming years as we continue to add strategic assets to each unit business and take full advantage of our new corporate structure. structure and business platform”.
About Valeo Pharma
Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on respiratory diseases, neurodegenerative diseases, oncology and specialty hospital products. Based at Kirkland, Quebec Valeo Pharma has all the required capabilities and the complete infrastructure to properly register and manage its growing product portfolio at all stages of commercialization. For more information, visit www.valeopharma.com and follow us on LinkedIn and Twitter.
This press release contains forward-looking statements about Valeo’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets in which we operate and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions prove to be inaccurate.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATORY SERVICE PROVIDER HAS REVIEWED NOR ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
SOURCEValeo Pharma Inc.
For further information: Steve Saviuk, CEO, 514-693-8830, [email protected]; Frederic Dumais, Director, Communications and Investor Relations, 514-261-4735, [email protected]